Showing 49 to 60 of 79 results
Russia Develops New Allergy Vaccine as Early Pollen Season Looms
A new birch pollen allergy vaccine is under development in Russia, potentially offering relief to 20-35% of the population who suffer from pollen allergies; an unusually warm winter may cause an early start to the pollen season in 2024.
Russia Develops New Allergy Vaccine as Early Pollen Season Looms
A new birch pollen allergy vaccine is under development in Russia, potentially offering relief to 20-35% of the population who suffer from pollen allergies; an unusually warm winter may cause an early start to the pollen season in 2024.
Progress
32% Bias Score
Brain Cancer Recurrence Prompts Clinical Trial
Professor Richard Scolyer, a 58-year-old Australian of the Year, faces potential recurrence of his aggressive brain cancer after a recent scan; surgery is scheduled for Monday to assess and potentially remove the tumor, though his prognosis remains 3-6 months, following an experimental treatment tha...
Brain Cancer Recurrence Prompts Clinical Trial
Professor Richard Scolyer, a 58-year-old Australian of the Year, faces potential recurrence of his aggressive brain cancer after a recent scan; surgery is scheduled for Monday to assess and potentially remove the tumor, though his prognosis remains 3-6 months, following an experimental treatment tha...
Progress
24% Bias Score
Personalized mRNA Vaccine Shows Promise Against Pancreatic Cancer
A small study shows a personalized mRNA vaccine may significantly improve pancreatic cancer survival rates by generating long-lasting T cells that target cancer cells; half the participants who had a strong immune response remained cancer-free for over three years, far exceeding typical survival rat...
Personalized mRNA Vaccine Shows Promise Against Pancreatic Cancer
A small study shows a personalized mRNA vaccine may significantly improve pancreatic cancer survival rates by generating long-lasting T cells that target cancer cells; half the participants who had a strong immune response remained cancer-free for over three years, far exceeding typical survival rat...
Progress
40% Bias Score
Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment
A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.
Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment
A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.
Progress
44% Bias Score
18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.
18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.
Progress
40% Bias Score
UV Light Irradiation Improves Cancer Immunotherapy Tolerability
A Freiburg University study shows UV light irradiation of immune cells significantly improves immunotherapy tolerability in cancer patients by reducing side effects like colitis, hepatitis, and dermatitis without hindering anti-tumor activity, impacting 14 patients across three German university hos...
UV Light Irradiation Improves Cancer Immunotherapy Tolerability
A Freiburg University study shows UV light irradiation of immune cells significantly improves immunotherapy tolerability in cancer patients by reducing side effects like colitis, hepatitis, and dermatitis without hindering anti-tumor activity, impacting 14 patients across three German university hos...
Progress
32% Bias Score
Injectable Drug Shows Superiority Over Oral Immunotherapy for Multiple Food Allergies
A Johns Hopkins Children's Center study found injectable omalizumab superior to oral immunotherapy for multiple food allergies; 36% of participants receiving omalizumab tolerated multiple allergens versus 19% with oral immunotherapy, highlighting improved safety and efficacy, with implications for t...
Injectable Drug Shows Superiority Over Oral Immunotherapy for Multiple Food Allergies
A Johns Hopkins Children's Center study found injectable omalizumab superior to oral immunotherapy for multiple food allergies; 36% of participants receiving omalizumab tolerated multiple allergens versus 19% with oral immunotherapy, highlighting improved safety and efficacy, with implications for t...
Progress
44% Bias Score
Brain Tumor Vaccine Shows Promise in Phase 1 Trial
A Phase 1 clinical trial in Heidelberg and Mannheim demonstrated that a new mutation-specific vaccine targeting IDH1 mutations in diffuse gliomas yielded positive results, with 84% of the 33 participants still alive three years after treatment, and 63% showing tumor stabilization.
Brain Tumor Vaccine Shows Promise in Phase 1 Trial
A Phase 1 clinical trial in Heidelberg and Mannheim demonstrated that a new mutation-specific vaccine targeting IDH1 mutations in diffuse gliomas yielded positive results, with 84% of the 33 participants still alive three years after treatment, and 63% showing tumor stabilization.
Progress
40% Bias Score
mRNA Vaccine Shows Promise in Extending Survival for Early-Stage Pancreatic Cancer
A clinical trial at Memorial Sloan Kettering successfully used a customized mRNA vaccine alongside surgery and chemotherapy to treat early-stage pancreatic cancer, resulting in significantly extended survival time for eight of sixteen patients who showed strong immune responses and only two recurren...
mRNA Vaccine Shows Promise in Extending Survival for Early-Stage Pancreatic Cancer
A clinical trial at Memorial Sloan Kettering successfully used a customized mRNA vaccine alongside surgery and chemotherapy to treat early-stage pancreatic cancer, resulting in significantly extended survival time for eight of sixteen patients who showed strong immune responses and only two recurren...
Progress
40% Bias Score
19-Year Remission Achieved in Neuroblastoma Patient Treated with CAR-T Cells
A 4-year-old girl treated for neuroblastoma in 2006 at Texas Children's Hospital with experimental CAR-T cell therapy remains cancer-free 19 years later, representing the longest remission ever reported for this treatment and offering new hope for solid tumor therapies.
19-Year Remission Achieved in Neuroblastoma Patient Treated with CAR-T Cells
A 4-year-old girl treated for neuroblastoma in 2006 at Texas Children's Hospital with experimental CAR-T cell therapy remains cancer-free 19 years later, representing the longest remission ever reported for this treatment and offering new hope for solid tumor therapies.
Progress
48% Bias Score
18-Year Cancer Remission Achieved with First-Generation CAR-T Therapy in Neuroblastoma Patient
An 18-year cancer remission in a neuroblastoma patient treated with first-generation CAR-T cell therapy at age four has been reported, exceeding previous remission records for both hematological and solid cancers, highlighting the therapy's potential for broader applications.
18-Year Cancer Remission Achieved with First-Generation CAR-T Therapy in Neuroblastoma Patient
An 18-year cancer remission in a neuroblastoma patient treated with first-generation CAR-T cell therapy at age four has been reported, exceeding previous remission records for both hematological and solid cancers, highlighting the therapy's potential for broader applications.
Progress
44% Bias Score
Veteran's Cancer Remission Highlights Immunotherapy Success
U.S. Navy veteran John Ryan, diagnosed with stage 4 lung cancer in 2013, achieved remission after 100 months of immunotherapy treatment, highlighting the effectiveness of this approach and the increased cancer risk among veterans.
Veteran's Cancer Remission Highlights Immunotherapy Success
U.S. Navy veteran John Ryan, diagnosed with stage 4 lung cancer in 2013, achieved remission after 100 months of immunotherapy treatment, highlighting the effectiveness of this approach and the increased cancer risk among veterans.
Progress
40% Bias Score
Showing 49 to 60 of 79 results